Search Results - "Puglisi, F"

Managing COVID-19 in the oncology clinic and avoiding the distraction effect by Cortiula, F., Pettke, A., Bartoletti, M., Puglisi, F., Helleday, T.

Get full text

Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype by Gerratana, L., Basile, D., Buono, G., De Placido, S., Giuliano, M., Minichillo, S., Coinu, A., Martorana, F., De Santo, I., Del Mastro, L., De Laurentiis, M., Puglisi, F., Arpino, G.

“…•The AR positive subtype has better prognosis and less chemotherapy responsiveness.•AR is involved in cell cycle regulation and Epithelial-to-Mesenchymal…”
Get full text

Checkpoint inhibitors, fertility, pregnancy, and sexual life: a systematic review by Garutti, M., Lambertini, M., Puglisi, F.

“…Immune checkpoint inhibitors (i.e. anti-PD1, anti-PDL1, and anti-CTLA4) have revolutionized the therapeutic approach of several cancer types. In a subset of…”
Get full text

A Novel Program-Verify Algorithm for Multi-Bit Operation in HfO2 RRAM by Puglisi, F. M., Wenger, C., Pavan, P.

“…In this letter, we propose a dispersion-aware program-verify algorithm to enable reliable multi-bit operations in HfO 2 -based RRAM. The significant intrinsic…”
Get full text

Pattern of metastasis and outcome in patients with breast cancer by Gerratana, L., Fanotto, V., Bonotto, M., Bolzonello, S., Minisini, A. M., Fasola, G., Puglisi, F.

“…There is growing evidence about differences in metastatic spread among breast cancer (BC) biologic subtypes (BS). Aim of this study was to analyze the pattern…”
Get full text

Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial by Malorni, L., Curigliano, G., Minisini, A.M., Cinieri, S., Tondini, C.A., D’Hollander, K., Arpino, G., Bernardo, A., Martignetti, A., Criscitiello, C., Puglisi, F., Pestrin, M., Sanna, G., Moretti, E., Risi, E., Biagioni, C., McCartney, A., Boni, L., Buyse, M., Migliaccio, I., Biganzoli, L., Di Leo, A.

“…The activity of palbociclib as a single agent in advanced breast cancer has not been extensively studied, with the only available clinical data limited to…”
Get full text

High-density neutrophils in MGUS and multiple myeloma are dysfunctional and immune-suppressive due to increased STAT3 downstream signaling by Romano, A., Parrinello, N. L., Simeon, V., Puglisi, F., La Cava, P., Bellofiore, C., Giallongo, C., Camiolo, G., D’Auria, F., Grieco, V., Larocca, F., Barbato, A., Cambria, D., La Spina, E., Tibullo, D., Palumbo, G. A., Conticello, C., Musto, P., Di Raimondo, F.

“…To understand neutrophil impairment in the progression from MGUS through active MM, we investigated the function of mature, high-density neutrophils (HDNs),…”
Get full text

Do platinum salts fit all triple negative breast cancers? by Gerratana, L, Fanotto, V, Pelizzari, G, Agostinetto, E, Puglisi, F

“…Highlights • The phenotype of BRCA wild-type TNBC often resembles the one of BRCA-related cancer. • BRCAness can be caused by epigenetic alterations or a RAD51…”
Get full text

Emerging molecular alterations leading to histology-specific targeted therapies in ovarian cancer beyond PARP inhibitors by Bartoletti, M., Musacchio, L., Giannone, G., Tuninetti, V., Bergamini, A., Scambia, G., Lorusso, D., Valabrega, G., Mangili, G., Puglisi, F., Pignata, S.

“…•PARP inhibitors have opened the era of targeted therapy in ovarian cancer;•Major therapeutic improvements have been limited to the high grade serous…”
Get full text

Exposure to low-dose rotenone precipitates synaptic plasticity alterations in PINK1 heterozygous knockout mice by Martella, G, Madeo, G, Maltese, M, Vanni, V, Puglisi, F, Ferraro, E, Schirinzi, T, Valente, E.M, Bonanni, L, Shen, J, Mandolesi, G, Mercuri, N.B, Bonsi, P, Pisani, A

“…Abstract Heterozygous mutations in the PINK1 gene are considered a susceptibility factor to develop early-onset Parkinson's disease (PD), as supported by…”
Get full text

Neoadjuvant chemotherapy for breast cancer in Italy: A Senonetwork analysis of 37,215 patients treated from 2017 to 2022 by De Luca, A., Amabile, M.I., Santori, F., Di Matteo, S., Tomatis, M., Ponti, A., Frusone, F., Taffurelli, M., Tinterri, C., Marotti, L., Calabrese, M., Marchiò, C., Puglisi, F., Palumbo, I., Fortunato, L.

“…Adoption of neoadjuvant chemotherapy (NACT) in the “real world” has been poorly investigated. Aim of this study was to examine the rate of NACT in Italy,…”
Get full text

Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review by Miglietta, F., Fabi, A., Generali, D., Dieci, M.V., Arpino, G., Bianchini, G., Cinieri, S., Conte, P.F., Curigliano, G., De Laurentiis, M., Del Mastro, L., De Placido, S., Gennari, A., Puglisi, F., Zambelli, A., Perrone, F., Guarneri, V.

“…[Display omitted] •Triple-negative metastatic breast cancer represents a challenging scenario.•Besides chemotherapy, several novel agents are now available in…”
Get full text

Boron Vacancies Causing Breakdown in 2D Layered Hexagonal Boron Nitride Dielectrics by Ranjan, A., Raghavan, N., Puglisi, F. M., Mei, S., Padovani, A., Larcher, L., Shubhakar, K., Pavan, P., Bosman, M., Zhang, X. X., O'Shea, S. J., Pey, K. L.

“…Dielectric breakdown in 2D insulating films for future logic device technology is not well understood yet, in contrast to the extensive insight we have in the…”
Get full text

Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treat. Rev. 114 (2023) 102511] by Miglietta, F., Fabi, A., Generali, D., Dieci, M.V., Arpino, G., Bianchini, G., Cinieri, S., Conte, P.F., Curigliano, G., De Laurentiis, M., Del Mastro, L., De Placido, S., Gennari, A., Puglisi, F., Zambelli, A., Perrone, F., Guarneri, V.

Get full text

Second-line treatment strategies for RAS wild-type colorectal cancer: A systematic review and Network Meta-analysis (NMA) by Di Nardo, P., Basile, D., Siciliano, A., Pelizzari, G., Corvaja, C., Buriolla, S., Ongaro, E., Maria Grazia, D., Garattini, S.K., Foltran, L., Guardascione, M., Casagrande, M., Buonadonna, A., Prantera, T., Aprile, G., Puglisi, F

“…The optimal strategy for second-line (IIL) treatment in KRAS wt metastatic colorectal cancer (mCRC) is not determined yet. A random-effect NMA of phase II/III…”
Get full text

Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treatm. Rev. 114 (2023) 102511] by Miglietta, F., Fabi, A., Generali, D., Dieci, M.V., Arpino, G., Bianchini, G., Cinieri, S., Conte, P.F., Curigliano, G., De Laurentiis, Michelino, Del Mastro, L., De Placido, S., Gennari, A., Puglisi, F., Zambelli, A., Perrone, F., Guarneri, V.

Get full text

Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers by Arecco, L, Bruzzone, M, Bas, R, Kim, H J, Di Meglio, A, Bernstein-Molho, R, Hilbers, F S, Pogoda, K, Carrasco, E, Punie, K, Bajpai, J, Agostinetto, E, Lopetegui-Lia, N, Partridge, A H, Phillips, K A, Toss, A, Rousset-Jablonski, C, Curigliano, G, Renaud, T, Ferrari, A, Paluch-Shimon, S, Fruscio, R, Cui, W, Wong, S M, Vernieri, C, Couch, F J, Dieci, M V, Matikas, A, Rozenblit, M, Aguilar-Y Méndez, D, De Marchis, L, Puglisi, F, Fabi, A, Graff, S L, Witzel, I, Rodriguez Hernandez, A, Fontana, A, Pesce, R, Duchnowska, R, Pais, H L, Sini, V, Sokolović, E, de Azambuja, E, Ceppi, M, Blondeaux, E, Lambertini, M

“…Hormone receptor expression is a known positive prognostic and predictive factor in breast cancer; however, limited evidence exists on its prognostic impact on…”
Get more information

Hype or hope? The strange case of platinum salts' renaissance in breast cancer by Corvaja, C., Garutti, M., Gerratana, L., Pelizzari, G., Puglisi, F.

Get full text

Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials by Dieci, M. V., Frassoldati, A., Generali, D., Bisagni, G., Piacentini, F., Cavanna, L., Cagossi, K., Puglisi, F., Michelotti, A., Berardi, R., Banna, G., Goubar, A., Ficarra, G., Griguolo, G., Conte, Pierfranco, Guarneri, V.

“…Purpose The aim was to evaluate the role of tumor-infiltrating lymphocytes (TIL) in predicting molecular response after preoperative endocrine or cytotoxic…”
Get full text

Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00 by Colleoni, Marco, Gray, Kathryn P, Gelber, Shari, Láng, István, Thürlimann, Beat, Gianni, Lorenzo, Abdi, Ehtesham A, Gomez, Henry L, Linderholm, Barbro K, Puglisi, Fabio, Tondini, Carlo, Kralidis, Elena, Eniu, Alexandru, Cagossi, Katia, Rauch, Daniel, Chirgwin, Jacquie, Gelber, Richard D, Regan, Meredith M, Coates, Alan S, Price, Karen N, Viale, Giuseppe, Goldhirsch, Aron

“…To evaluate the benefit of low-dose cyclophosphamide and methotrexate (CM) maintenance, which previously demonstrated antitumor activity and few adverse…”
Get full text